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OBJECTIVES: To conduct a study to assess value perceptions
and the evidence needs for key stakeholders of medical product
manufacturers, including payers and employers. This study was
a structured, qualitative assessment of inﬂuential U.S. health
plans and companies. METHODS: Telephone survey interviews
were used to collect data from ﬁfteen private U.S. payer re-
presentatives and payer-related experts. Phone and in-person
interviews were conducted with twenty-six U.S. employer 
representatives. Working behavioral assumptions were con-
structed for the payer and employer groups, and stakeholder-
speciﬁc discussion guides were used to facilitate the survey 
interviews. RESULTS: The top payer ﬁndings suggest that health
plans are most interested in clinical safety, efﬁcacy, and effec-
tiveness evidence. Payers’ demands are increasing for more 
clinical utility and clinical performance studies providing 
comparative information for medical products. Cost and cost-
effectiveness were identiﬁed as important but secondary con-
siderations for coverage and reimbursement decisions. The
employers surveyed exhibited substantial diversity in their
approach to providing health care beneﬁts for employees. The
majority of employers and payers reported that consumer-
directed health care (CDHC) plans are increasing in scope and
will play a larger role moving forward. Most reported that the
effects of CDHC on costs and long-term health outcomes are
unclear. Recent trends associated with health care costs increas-
ing faster than inﬂation contribute to employers’ difﬁculty with
deﬁning “value in health care” and to their challenges associated
with evaluating return on investment for health care expendi-
tures. CONCLUSION: U.S. employers and payers are struggling
with clearly deﬁning the concept of medical product value.
Payers rely on phase III randomized controlled trials as their
primary evidence source for covering medical products, yet
request additional post-marketing comparative studies. Employ-
ers are largely engaged in cost-shifting to employees and are
trying to select younger and healthier workforces to reduce their
health care expenditures.
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THE VOLUNTARY INCENTIVE STRUCTURE OF PEDIATRIC
EXCLUSIVITY AND ITS IMPACTS ON PHARMACEUTICAL
INDUSTRY BEHAVIOR AND GENERIC DRUG ENTRIES
Rhee J
UCLA, Los Angeles, CA, USA
OBJECTIVES: The FDA Modernization Act of 1997 created a
six-month of market exclusivity extension in exchange for phar-
maceutical companies’ pediatric studies for the drugs of poten-
tial beneﬁts to the pediatric population. This study examines
how the voluntary incentive structure of the exclusivity has
impacted on the pharmaceutical industry’s efforts to obtain the
exclusivity and how the rule has been used to delay generic
entries for the exclusivity period. METHODS: By using 63 drugs
whose patent expired between 1999 and 2003, obtained from
the FDA, several descriptive analyses were performed. The per-
centage of drugs with pediatric exclusivity was described by
several important factors, especially focusing on main use of the
drugs. Next, all the drugs were divided into two groups—drugs
with exclusivity vs. no exclusivity—and then generic competition
degree was presented by each group for two years following the
initial patent expiration of each drug. RESULTS: A bigger ﬁrm
was good at ﬁling the exclusivity that needs additional clinical
study (p < 0.05). The competition level in each drug’s therapeu-
tic class was positively associated with having the exclusivity.
The drugs with exclusivities were more likely to treat chronic
conditions that include many blockbuster drugs. The ﬁrms have
applied for pediatric extension over the drugs with larger market
size (p < 0.01). For pediatric exclusivity group, there were no
generic competitors until six months and then there was a dra-
matic increase of generic entries after the exclusivity expired
whereas no-pediatric group didn’t show notable increasing trend
during the observation period. CONCLUSION: The market size
of a drug was the most important factor to acquire the pediatric
exclusivity that has been a tool for an originator ﬁrm to delay
generic competition. It implies the incentive structure based on
willingness of industry has not always achieved the primary goal
of “safety of children”.
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DIFFERENCES IN CHRONIC DISEASE CARE OF
PRE_MEDICARE INDIVIDUALS BETWEEN METROPOLITAN
AND NON-METROPOLITAN SETTINGS
Raoﬁ S
Centers for Disease Control and Prevention, Hyattsville, MD, USA
OBJECTIVES: Differences between metropolitan and non-
metropolitan setting in the management of chronic conditions 
in patients 55 to 64 years of age can result in higher morbidity
rates in non-metropolitan areas. We will look at the association
between the geographic setting and indicators of care manage-
ment for visits in this population. METHODS: Data from the
National Ambulatory Medical Care and National Hospital
Ambulatory Medical Care (outpatient department) surveys were
combined for years 2001 to 2004. NAMCS and NHAMCS
collect visit data from medical records of randomly selected
physician ofﬁces, hospital outpatient departments, and hospital
emergency departments during randomly selected time periods
through the year. A metropolitan area is an urban area with a
core population of at least 50,000. Visit data were weighted by
the inverse of selection probability and used to provide annual
average estimates. Visits having diagnoses codes for hyperten-
sion, diabetes, COPD, heart disease, stroke, and cancer were
selected based on the ICD-9-CM codes. Number of chronic dis-
eases, medications mentioned, therapeutic and preventive ser-
vices performed, and diagnostic procedures ordered per visit
were compared between metropolitan and non-metropolitan set-
tings. SUDAAN software was used to develop a Poison regres-
sion model to perform the comparisons. Source of payment,
gender, and race for patients were included in the model as
covariates. The effect of the number of previous visits on the out-
comes will be examined in future. RESULTS: Although rural
visits had a higher number of chronic conditions (1.14 vs. 1.11,
p < 0.05), they had a smaller number of therapeutic and pre-
ventive services performed per visit (1.22 vs. 2.73, p < 0.01) and
had a lower number of diagnostic and screening procedures
ordered per visit (2.61 vs. 3.04, p < 0.05). CONCLUSION: The
differences in care management in the years preceding Medicare
eligibility could have implications for utilization of services once
this population enrolls in Medicare.
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THE TRENDS IN PRESCRIBING OF HERBAL MEDICINES IN
AMBULATORY SETTINGS IN THE UNITED STATES 1993–2004
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OBJECTIVES: The use and awareness of herbal medicines has
been on the rise. Although most of these products are over the
counter (OTC), it is less known how often they are recom-
mended during ofﬁce-based physician visits. Purpose: The objec-
tive of this study was to investigate the trends in prescribing of
herbal medicines in the ambulatory medical setting in the U.S.
METHODS: This study was a retrospective analysis of the
National Ambulatory Medical Care Survey (NAMCS) and 
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the National Hospital Ambulatory Medical Care Survey
(NHAMCS) data from 1993 through 2004. Both are national
probability surveys of visits to ofﬁce-based physicians and ambu-
latory services in hospital emergency and outpatient departments
and provide weights to obtain nationally representative esti-
mates. Seventy-six different medicines of herbal origin were iden-
tiﬁed based on their generic codes and the visits in which they
were prescribed were calculated for each year. RESULTS: In
1993, of the total 1.6 billion NAMCS & NHAMCS visits, her-
bal medication was prescribed in 0.14% ambulatory visits
[2,328,901 (95% C.I.: 2,298,097–2,359,705)]. This proportion
increased to 0.26% in 2004 or 2,883,006 visits (95% C.I.:
2,821,529–2,944,483) of the total 1.1 billion visits. The ﬁve
most commonly prescribed medications were Psyllium, Senna,
Garlic, Ginkgo and Ipecac. Forty-nine of the total seventy-six
study drugs were never prescribed during a physician visit
throughout the study period. CONCLUSION: The trend of pre-
scribing of herbal medications during ofﬁce-based physician
visits has risen over the past decade but is limited to selected
herbal products and is not widepread.
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COSTS
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1Mexican Institute of Social Security, Mexico City, Mexico, 2National
Autonomous University of Mexico, México City, Mexico City, Mexico
OBJECTIVES: To identify cases of polypharmacy (PF) and to
describe their social and clinical characteristics, satisfaction and
costs in elderly patients who attended Family Medicine health
care services at the Mexican Institute of Social Security (IMSS).
METHODS: Cross sectional study in 260 elders (°Y´ 65 years
old) who attended a Family Medicine facility at the IMSS in
Mexico City. A survey and a concurrent review of medical
records were performed to identify characteristics of drug pre-
scription and patients’ satisfaction in the previous 3 months. The
WHO deﬁnition of polypharmacy was used to classify this pre-
scribing pattern: simultaneously consumption of more than 3
drugs. Costs were estimated from an institutional perspective
and are expressed in US dollars (USD). RESULTS: Mean age was
71 years (6.9 SD), 60.8% were female, 15.8% illiterate, 53.5%
married, 10.4% single and 35.4% widow/widower. A high per-
centage (86.2%) reported having a chronic disease; the main
problems were hypertension (57.7%), diabetes (35.4%), and
sleep problems (35.4%). Satisfaction with medication was: very
high 56.9%, high 28.5%, mild 8.1%, low 1.2%, and very low
0.8%. Drug mean cost per patient was 6.6 USD (per month) with
a maximum of 61.8 USD. Prescription of 3 drugs at the same
time was reported in 64.2% and polypharmacy in 49.2% CON-
CLUSION: Our study found that polypharmacy was a common
prescribing pattern in Family Medicine services. Prescription of
3 drugs at the same time and polypharmacy might lead to an
important proportion of health care costs. Among the elderly
population the proportion of chronic conditions was high, as
was satisfaction with drug treatment. It is possible that there is
a trade-off between improvement of symptoms and adverse side
effects of drugs; therefore it would be necessary to research the
quality of life, drug prescription and its justiﬁcation in these
patients.
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STUDYING THE IMPACT OF CO-PAYMENT DIFFERENTIAL ON
GENERIC DISPENSING RATE IN A MANAGED CARE
POPULATION
Meller CP, Sekula R, Khandelwal NG, Lee KY
Walgreens Health Services, Deerﬁeld, IL, USA
OBJECTIVES: The purpose of this study was to determine the
impact of copayment differential between tier-one and tier-two
medications on the generic dispensing rates. METHODS: A pre-
post study design with control group analysis was conducted to
investigate the effect of a changing copayment structure on the
Generic Dispensing Rate (GDR). Clients that changed their
copayment structure during the 2006 ﬁscal year were identiﬁed.
Data from ﬁve clients from pharmacy claims database main-
tained by a large pharmacy beneﬁt manager (PBM) were col-
lected. Study clients had one of the three effective dates during
which they changed their copayment structures: January 1, 2006;
July 1, 2006; or October 1, 2006. Two clients that did not change
their copayment in 2006 were included as control groups. Dif-
ferences in the copayment amount and percentage change in
GDR for pre and post periods were computed and compared
using independent t-tests. In addition, an adjusted GDR was cal-
culated by subtracting a nominal increase in the control groups
from each of the study groups. RESULTS: Clients that changed
their copayment structure in January 1, 2006 reported a mean
GDR increase of 2.36% with a mean $8.32 increase in their
copayment amount (p-value < 0.05). Similarly, clients who
changed their copayment structure in July 1, 2006 demonstrated
a mean GDR increase of 4.06% with a mean $9.13 increase in
their copayment amount (p-value < 0.05). While clients that
changed their copayment structure during October 1, 2006
period showed a net increase in GDR of 2.7% with a $3.36
increase in copayment amount. Such changes were also found to
be statistically signiﬁcant when compared to the changes
reported by the control clients. CONCLUSION: Increasing the
copayment amount between tier-one and tier-two demonstrated
a positive impact on GDR thereby translating into potential
savings for the clients.
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OBJECTIVES: To compare generic dispensing rate (GDR)
among 30-day retail program, mandatory 90-day retail program
and voluntary 90-day retail program. METHODS: This analy-
sis was conducted using pharmacy claims data from a pharmacy
beneﬁt manager (PBM). Patients who were new to either Ace-
Inhibitor, statins or SSRIs in March-May 2005 were identiﬁed
and followed-up for a period of 12-month to measure their
GDR. Patients had retail 30-day supply only during the study
period were included in 30-day retail program, patients had
mandatory 90-day supply during the study period were in
mandatory 90-day retail program, and similarly, patients had
voluntary 90-day supply were in voluntary 90-day retail
program. GDR was measured by claim level as well as patient
level, which was the number of generic claims and/or patients
using generic medications divided by total number of claims
and/or total patients. All claims were normalized to a 30-day
supply. RESULTS: About 4678 claims and 907 patients in 30-
day retail program, 1438 claims and 138 patients in mandatory
90-day retail program, 5136 claims and 538 patients in volun-
tary 90-day retail program. GDR was found to be relatively
higher in voluntary 90-day retail program (47.65%, 47.77%),
